Skip to content

CONNECTING PHARMA

Active Private limited companyfounded 2012active for 14 yearsEdmond Boonenstraat 4, 9000 GhentKBO/BCE: BE 0846.826.628

Lifetime

12 annual accounts with figures on one time axis
peak of €235,080 in 2014
€68,483▲ 27.1%
peak of €174,786 in 2014
€44,241▲ 48.9%
peak of €305,388 in 2023
€137,271▼ 26.5%
€175,072▲ 4.7%
Board1 name since 2012
1 director
Documentsfilings and deeds
25-06-202636 days before the deadline
2025micro format
Gross margin from €53,879 to €68,483Result from €29,717 to €44,241Dividend €93,782Equity from €186,811 to €137,271

Key points

from the 2025 annual accounts

Equity

€137,271 ▼ 26.5%
186,8112024+44,241Profit-93,782Dividend137,2712025

CONNECTING PHARMA paid out €93,782 in dividends. That is 212% of the 2025 profit.

Turnover

≈ €140,000 estimated

The micro format states no turnover.

Filings

12 annual accounts since 2014
AprilJune31 JulyOctober201520202025

The 2019 accounts came 31 days late. The other nine of the last ten were filed on time.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 34,724 companies had the same profile as CONNECTING PHARMA has now. Each dot stands for 87 companies, two years later.

95.3%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,894 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,724 companies, not a prediction for CONNECTING PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Manager
  • 186 sharesdeed of 25-04-2023
Board & ownership

Recent changes

Merger: ASCLEPIA OUTSOURCING SOLUTIONS takes over CONNECTING PHARMA Company renamed from ASCLEPIA OUTSCOURCING SOLUTIONS to CONNECTING PHARMA · changes role from director to statutory director · reappointed as statutory director · General meeting of 30-05-2023 · Gazette deed
Merger proposal: Asclepia Outsourcing Solutions takes over Connecting Pharma BV The company holds 100 shares of Connecting Pharma BV · holds 186 shares · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0846826628
Registered office moved from Destelbergen to Ghent The registered office moved from Damvaleistraat 49 te 9070 Destelbergen to Edmond Boonenstraat 4 te 9000 Gent · General meeting of 30-10-2019 · Gazette deed
All 23 events

Comparable companies

same main activity, similar in size and age
Company
CONNECTING PHARMA Ghent €312,342 €68,483 43.9% -
studio ratio Ghent €331,221 €67,606 98.4% -
Long Gamma Ghent €310,613 €62,307 44.3% -
Litypic Ghent €358,204 €80,443 93.9% -
XIV Ghent €275,677 €81,832 67.2% -
DenS Communicatie Ghent €372,775 €63,681 81.9% -
François Consulting Sint-Lievens-Houtem €306,441 €69,627 71.0% -

These companies have the same main activity as CONNECTING PHARMA: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €276,000 and €373,000, founded between 2010 and 2013.

Official details

Source: KBO
Status
Active since 20-06-2012Normal situation
Activity
Business and other management consultancyNACE 70200and 5 others
Establishment unit
2.211.815.7749000 Ghent, registered on 20-06-2012
Financial year end
31 December
Peppol
Reachable since 03-03-2023
Company details

Annual accounts 2025

€312,342▼ 11.8%
Filing
Filed on 25-06-2026, 36 days before the end of the filing period
Financials

Insights on CONNECTING PHARMA

CONNECTING PHARMA files the micro format. That format states no turnover. The gross margin fell from €235,080 in 2014 to €68,483 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about CONNECTING PHARMA

What is the company number of CONNECTING PHARMA?
The company number of CONNECTING PHARMA is 0846.826.628. The VAT number is the same number with BE in front: BE 0846.826.628.
Where is CONNECTING PHARMA based?
The registered office is at Edmond Boonenstraat 4, 9000 Ghent.Company details
What does CONNECTING PHARMA do?
According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
What is the legal form of CONNECTING PHARMA?
CONNECTING PHARMA is a private limited company (BV).
When was CONNECTING PHARMA founded?
CONNECTING PHARMA was founded on 20-06-2012.
Is CONNECTING PHARMA still active?
Yes, CONNECTING PHARMA is an active enterprise in the KBO register.
What is the turnover of CONNECTING PHARMA?
The turnover in financial year 2025 is about €140,000. This figure is estimated from the gross margin of €68,483 and 137 comparable companies (NACE 70200). It probably lies between €100,000 and €180,000.Financials
Is CONNECTING PHARMA profitable?
In financial year 2025, CONNECTING PHARMA made a profit of €44,241.
Where can I find the annual accounts of CONNECTING PHARMA?
CONNECTING PHARMA filed 12 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of CONNECTING PHARMA due?
CONNECTING PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.